Back to top
more

Regeneron Pharmaceuticals (REGN)

(Real Time Quote from BATS)

$992.70 USD

992.70
106,979

+5.43 (0.55%)

Updated May 21, 2024 12:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Regeneron (REGN) Reports Q4 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Regeneron (REGN) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

Regeneron (REGN) delivered earnings and revenue surprises of 13.71% and 5.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Roche (RHHBY) 2023 Earnings Miss, COVID-19 Product Sales Down

by Zacks Equity Research

Roche (RHHBY) misses earnings and sales estimates in 2023 due to a significant decline in COVID-19-test sales. Currency rate fluctuations also impact results.

Sanofi (SNY) Misses on Q4 Earnings and Sales, Stock Down

by Zacks Equity Research

Sanofi (SNY) misses fourth-quarter estimates for earnings and sales. It maintains 2024 earnings growth guidance.

Biotech Stock Roundup: GSK's Q4 Results, VRTX Gains on Update, TSVT Up on REGN Deal

by Zacks Equity Research

Earnings from GSK and other updates from 2seventy bio (TSVT) were in focus in the biotech sector.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

Regeneron (REGN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when Regeneron (REGN) reports its fourth-quarter 2023 results.

2seventy bio (TSVT) Divests R&D Assets to Regeneron, Stock Up

by Zacks Equity Research

2seventy bio (TSVT) inks an asset purchase agreement with Regeneron to sell its oncology and autoimmune pipeline to the latter.

Novartis (NVS) Q4 Earnings Miss on Higher Costs, Sales Lag

by Zacks Equity Research

Novartis' (NVS) earnings and sales miss estimates in the fourth quarter. The outlook for 2024 does not look promising as well.

Pfizer (PFE) Q4 Earnings Top, Revenues Miss on COVID Sales Slump

by Zacks Equity Research

Pfizer (PFE) reports mixed fourth-quarter 2023 results. It re-affirms its 2024 sales and earnings guidance provided in December 2023.

Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Deciphera Pharmaceuticals, Inc. (DCPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Gear Up for Regeneron (REGN) Q4 Earnings: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.

Fate Therapeutics (FATE) Soars 25.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Fate Therapeutics (FATE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Will New Drugs Drive Pfizer (PFE) Sales in Q4 Earnings?

by Zacks Equity Research

Investor focus is likely to be on the sales numbers of Pfizer's (PFE) several newly launched drugs like Abrysvo, Velsipity, Penbraya as well as newly acquired products like Nurtec and Oxbryta on the fourth-quarter earnings call.

Nalak Das headshot

5 U.S. Corporate Giants to Buy on Solid Economic Data

by Nalak Das

We have narrowed our search to five U.S. corporate giants that have strong potential for 2024. These are: NFLX, PGR, BK, ANET, REGN.

Earnings Preview: Regeneron (REGN) Q4 Earnings Expected to Decline

by Zacks Equity Research

Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SpringWorks (SWTX) Surges More Than 80% in 3 Months: Here's Why

by Zacks Equity Research

SpringWorks (SWTX) receives a big boost with the FDA's approval for Ogsiveo (nirogacestat) to treat adult patients with progressing desmoid tumors.

Should You Invest in the iShares Biotechnology ETF (IBB)?

by Zacks Equity Research

Sector ETF report for IBB

Travere (TVTX) Stock Up More Than 30% in 3 Months: Here's Why

by Zacks Equity Research

Travere (TVTX) is on track to file an sNDA to the FDA to convert the accelerated approval for lead drug, Filspari, to full approval for IgAN in first-quarter 2024.

Here's Why Investors May Bet on BioMarin (BMRN) Stock Now

by Zacks Equity Research

Here, we discuss some reasons why investing in BioMarin (BMRN) stock now may turn out to be a more prudent move than ever.

Outlook (OTLK) Surges 31% on Regulatory Update for AMD Study

by Zacks Equity Research

Outlook (OTLK) stock rises after aligning with the FDA regarding the protocols of a non-inferiority study of ONS-5010 for AMD. The study is set to become the basis for BLA resubmission by 2024-end.

Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why

by Zacks Equity Research

Lisata (LSTA) is progressing well with the development of its lead investigational product candidate, LSTA1, which targets several cancer indications.

Mirum (MIRM) Banks on Livmarli Sales Despite Recent Setback

by Zacks Equity Research

Mirum's (MIRM) lead drug, Livmarli, continues to generate steady sales. The company's efforts to expand the label of the drug are also encouraging. However, pipeline setback remains a concern.

Gilead (GILD) Down as NSCLC Study Fails to Meet Primary Goal

by Zacks Equity Research

Gilead Sciences' (GILD) phase III study evaluating Trodelvy (sacituzumab govitecan) in previously treated metastatic NSCLC fails to meet its primary endpoint. Shares decline on the same.

J&J's (JNJ) Q4 Earnings Beat, Darzalex, Stelara Drive Sales

by Zacks Equity Research

J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sales of several key drugs like Darzalex, Stelara and Tremfya beat estimates.